Xylem (NYSE: XYL) reported Q1 EPS of $0.48, $0.10 better than the analyst estimate of $0.38. Revenue for the quarter came in at $1.26 billion versus the consensus estimate of $1.17 billion.

“Our Xylem team performed exceptionally well in the first quarter, despite ongoing pandemic challenges around the world. I’m so proud of how the team has served our customers and communities,” said Patrick Decker, Xylem’s president and CEO. “We came into the year with growing momentum, and are taking full advantage of resurgent demand alongside broader economic recovery, posting double-digit orders growth across all segments.”

“The positive market signals we are seeing, and our team’s proven ability to manage through a challenging supply chain environment, give us confidence about the remainder of this year and beyond. On that basis, we are raising our guidance for the full year, for both top-line growth and earnings.”

GUIDANCE:

Xylem sees FY2021 EPS of $2.50-$2.70, versus the consensus of $2.56.

Xylem now expects full year organic revenue growth to be in the range of 5 to 7 percent, and 8 to 10 percent on a reported basis. This represents an increase from the Company’s previous full-year organic revenue guidance of 3 to 5 percent, and 6 to 8 percent on a reported basis. Full-year adjusted earnings per share is now expected to be in the range of $2.50 to $2.70, up from the previous range of $2.35 to $2.60. The increased guidance primarily reflects commercial momentum and broad demand recovery.

For earnings history and earnings-related data on Xylem (XYL) click here.